128253-32-7
Chemical Structure
(S)-Veliflapon
Synonym(s): (S)-BAY X 1005; (S)-DG-031
- CAS No.: 128253-32-7
- Formula:C23H23NO3
- Molecular Weight:361.43
IUPAC Name: (S)-2-cyclopentyl-2-(4-(quinolin-2-ylmethoxy)phenyl)acetic acid
InChIKey: ZEYYDOLCHFETHQ-QFIPXVFZSA-N
SMILES: O=C(O)[C@@H](C1CCCC1)C(C=C2)=CC=C2OCC3=NC4=CC=CC=C4C=C3
Biological Activity: (S)-Veliflapon ((S)-BAY X 1005) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(S)-Veliflapon | 99.25% | (S)-Veliflapon ((S)-BAY X 1005) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95. [Content Brief]
- [2]. Hermann, David J., et al. Dosing schedules of leukotriene synthesis inhibitors for human therapy. World Intellectual Property Organization. WO2009002746.
- [3]. Helgadottir, et al. Polymorphisms in the susceptibility genes for myocardial infarction, stroke, and peripheral artery occlusive disease and their use in risk assessment and prophylaxis therapy. United States. US20070280917.
